Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends. Read more about Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends.
Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. Read more about Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes.
Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials. Read more about Does One Size Fit All? Re-evaluating Prostate-specific Antigen Progression Thresholds for Clinical Trials.
Apalutamide and Overall Survival in Prostate Cancer. Read more about Apalutamide and Overall Survival in Prostate Cancer.
Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Read more about Reply to Roderick C.N. van den Bergh, Olivier Rouvière, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not
Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. Read more about Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51. Read more about Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. Eur Urol 2020;78:443-51.
Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Read more about Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.
Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence. Read more about Routine Use of Magnetic Resonance Imaging for Early Detection of Prostate Cancer Is Not Justified by the Clinical Trial Evidence.
Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells. Read more about Expression of ACE2, the SARS-CoV-2 Receptor, and TMPRSS2 in Prostate Epithelial Cells.
